Published in J Pharmacol Exp Ther on July 05, 2006
A Multicenter Study of NAP (AL-108) in Schizophrenia (AL-108) | NCT00505765
NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy. Mol Psychiatry (2013) 0.94
Zinc and glutamine improve brain development in suckling mice subjected to early postnatal malnutrition. Nutrition (2010) 0.89
NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42). BMC Neurosci (2008) 0.86
VIP-induced neuroprotection of the developing brain. Curr Pharm Des (2011) 0.81
NAP protects against cyanide-related microtubule destruction. J Neural Transm (Vienna) (2009) 0.80
Anti-Inflammatory Properties of NAP in Acute Toxoplasma Gondii-Induced Ileitis in Mice. Eur J Microbiol Immunol (Bp) (2015) 0.77
The Eight and a Half Year Journey of Undiagnosed AD: Gene Sequencing and Funding of Advanced Genetic Testing Has Led to Hope and New Beginnings. Front Endocrinol (Lausanne) (2017) 0.76
Neonatal Hypoxia Ischaemia: Mechanisms, Models, and Therapeutic Challenges. Front Cell Neurosci (2017) 0.76
Prolonged maternal separation induces undernutrition and systemic inflammation with disrupted hippocampal development in mice. Nutrition (2016) 0.75
Positive screening for autism in ex-preterm infants: prevalence and risk factors. Pediatrics (2008) 3.74
Fluctuating pressure-passivity is common in the cerebral circulation of sick premature infants. Pediatr Res (2007) 2.02
Does cerebellar injury in premature infants contribute to the high prevalence of long-term cognitive, learning, and behavioral disability in survivors? Pediatrics (2007) 2.00
PRRT2 mutations cause benign familial infantile epilepsy and infantile convulsions with choreoathetosis syndrome. Am J Hum Genet (2012) 1.91
Late gestation cerebellar growth is rapid and impeded by premature birth. Pediatrics (2005) 1.87
Current definitions of hypotension do not predict abnormal cranial ultrasound findings in preterm infants. Pediatrics (2007) 1.65
Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol (2012) 1.64
Cranial ultrasound lesions in the NICU predict cerebral palsy at age 2 years in children born at extremely low gestational age. J Child Neurol (2009) 1.59
Neonatal seizure recognition--comparative study of continuous-amplitude integrated EEG versus short conventional EEG recordings. Clin Neurophysiol (2011) 1.56
Video and CD-ROM as a training tool for performing neurologic examinations of 1-year-old children in a multicenter epidemiologic study. J Child Neurol (2005) 1.49
A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther (2008) 1.41
Impaired trophic interactions between the cerebellum and the cerebrum among preterm infants. Pediatrics (2005) 1.39
Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res (2003) 1.38
Relationship Between Central Hypotonia and Motor Development in Infants Attending a High-Risk Neonatal Neurology Clinic. Pediatr Phys Ther (2016) 1.38
Neurodevelopmental outcome of children with intrauterine growth retardation: a longitudinal, 10-year prospective study. J Child Neurol (2007) 1.38
Cerebellar hemorrhage in the preterm infant: ultrasonographic findings and risk factors. Pediatrics (2005) 1.32
Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther (2007) 1.30
Significance of microcephaly among children with developmental disabilities. J Child Neurol (2002) 1.28
NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis (2009) 1.26
Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci (2007) 1.24
Cerebral hemodynamic changes during intensive care of preterm infants. Pediatrics (2008) 1.22
Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev Biol (2006) 1.14
Elevated cerebral pressure passivity is associated with prematurity-related intracranial hemorrhage. Pediatrics (2009) 1.12
A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem (2004) 1.12
Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J Biol Chem (2007) 1.12
Neuropsychological outcome of children with intrauterine growth restriction: a 9-year prospective study. Pediatrics (2006) 1.10
Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem (2006) 1.08
PolyADP-ribosylation is involved in neurotrophic activity. J Neurosci (2005) 1.06
PolyADP-ribosylation is required for long-term memory formation in mammals. J Neurochem (2009) 1.03
NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke (2002) 1.01
Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide. Antimicrob Agents Chemother (2002) 1.01
Closure of skin incisions in rabbits by laser soldering: I: Wound healing pattern. Lasers Surg Med (2004) 1.00
Neuroprotective protein and carboxypeptidase E. J Mol Neurosci (2009) 0.99
A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol Cell Neurosci (2010) 0.98
ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. J Mol Neurosci (2008) 0.98
Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein. Brain Res Rev (2006) 0.97
Protective peptides that are orally active and mechanistically nonchiral. J Pharmacol Exp Ther (2004) 0.97
Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol (2004) 0.96
Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. J Mol Neurosci (2005) 0.95
Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. Eur Neuropsychopharmacol (2010) 0.95
NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol Dis (2013) 0.94
Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Neurobiol Dis (2011) 0.93
NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis. Curr Pharm Des (2007) 0.92
Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett (2004) 0.92
In vivo visualization of white matter fiber tracts of preterm- and term-infant brains with diffusion tensor magnetic resonance imaging. Invest Radiol (2005) 0.92
NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function. Ann N Y Acad Sci (2006) 0.91
Memory functions of children born with asymmetric intrauterine growth restriction. Brain Res (2006) 0.91
The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. PLoS One (2012) 0.90
Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat (2012) 0.90
Novel evolutionary-conserved role for the activity-dependent neuroprotective protein (ADNP) family that is important for erythropoiesis. J Biol Chem (2012) 0.90
Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. J Mol Neurosci (2007) 0.89
Cerebellar injury in term infants: clinical characteristics, magnetic resonance imaging findings, and outcome. Pediatr Neurol (2009) 0.89
The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci (2005) 0.88
Neurodevelopmental and cognitive assessment of children born growth restricted to mothers with and without preeclampsia. Hypertens Pregnancy (2003) 0.88
NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia. Peptides (2010) 0.87
NAP protects against cytochrome c release: inhibition of the initiation of apoptosis. Eur J Pharmacol (2009) 0.87
Hypertension and neuronal degeneration in excised rat spinal cord studied by high-b value q-space diffusion magnetic resonance imaging. Exp Neurol (2003) 0.87
Growth patterns in children with intrauterine growth retardation and their correlation to neurocognitive development. J Child Neurol (2009) 0.86
Pseudotumor cerebri - idiopathic intracranial hypertension in the pediatric population. Pediatr Endocrinol Rev (2006) 0.86
The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide. Peptides (2003) 0.86
Diagnosis of inferior vermian hypoplasia by fetal magnetic resonance imaging: potential pitfalls and neurodevelopmental outcome. Am J Obstet Gynecol (2006) 0.86
Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. J Mol Neurosci (2009) 0.86
Tau and caspase 3 as targets for neuroprotection. Int J Alzheimers Dis (2012) 0.86
Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regul Pept (2004) 0.86
Gene-expression-based analysis of local and metastatic neuroblastoma variants reveals a set of genes associated with tumor progression in neuroblastoma patients. Int J Cancer (2010) 0.86
Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr Pharm Des (2011) 0.86
Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer. Curr Pharm Des (2007) 0.85
Cerebral palsy--long-term medical, functional, educational, and psychosocial outcomes. J Child Neurol (2009) 0.85
Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress. J Neurochem (2007) 0.84
Complex array of cytokines released by vasoactive intestinal peptide. Neuropeptides (2003) 0.84
A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes. Life Sci (2002) 0.84
(N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist. J Mol Neurosci (2002) 0.83
NAP protects hippocampal neurons against multiple toxins. Peptides (2007) 0.83
Winging of the scapula in a child with hereditary multiple exostoses. Pediatr Neurol (2002) 0.83
Generation and characterization of novel local and metastatic human neuroblastoma variants. Neoplasia (2008) 0.82
The pregnant spontaneously hypertensive rat as a model of asymmetric intrauterine growth retardation and neurodevelopmental delay. Hypertens Pregnancy (2005) 0.82
The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy. J Neurochem (2009) 0.82
Antenatal diagnosis of central nervous system anomalies: can we predict prognosis? J Child Neurol (2004) 0.81
Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP). Neuropeptides (2013) 0.81
Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. J Mol Neurosci (2006) 0.81
VIP provides cellular protection through a specific splice variant of the PACAP receptor: a new neuroprotection target. Peptides (2006) 0.81
Macrocephaly in children with developmental disabilities. Pediatr Neurol (2002) 0.81
Intrauterine growth-restricted neonates born at term or preterm: how different? Pediatr Neurol (2011) 0.81
The effects of vascular intrauterine growth retardation on cortical astrocytes. J Matern Fetal Neonatal Med (2010) 0.81
Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability. J Pept Sci (2008) 0.81
Large in-frame deletions of the rod-shaped domain of the dystrophin gene resulting in severe phenotype. Isr Med Assoc J (2003) 0.81
Telmisartan in the treatment of Cohen-Rosenthal Diabetic Hypertensive rats: the benefit of PPAR-gamma agonism. Clin Exp Hypertens (2007) 0.81
Antagonism of VIP-stimulated cyclic AMP formation in chick brain. J Mol Neurosci (2003) 0.81
Endocrine profile of children with intrauterine growth retardation. J Pediatr Endocrinol Metab (2005) 0.81
New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia. Autophagy (2014) 0.81
Blood pressure values in 8-12 year old children with a history of intrauterine growth retardation. Isr Med Assoc J (2011) 0.80
Neuropeptide receptor transcripts are expressed in the rat clitoris and oscillate during the estrus cycle in the rat vagina. Peptides (2005) 0.80
Looking for novel ways to treat the hallmarks of Alzheimer's disease. Expert Opin Investig Drugs (2007) 0.80
NAP protects against cyanide-related microtubule destruction. J Neural Transm (Vienna) (2009) 0.80